Quadrature Capital Ltd Has $553,000 Position in Envista Holdings Co. (NYSE:NVST)

Quadrature Capital Ltd lessened its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 68.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 27,981 shares of the company’s stock after selling 61,078 shares during the period. Quadrature Capital Ltd’s holdings in Envista were worth $553,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Envista during the third quarter valued at approximately $31,000. GAMMA Investing LLC boosted its stake in Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares in the last quarter. Huntington National Bank increased its holdings in Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after buying an additional 949 shares during the period. Blue Trust Inc. raised its stake in shares of Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after buying an additional 804 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock worth $43,000 after acquiring an additional 728 shares during the period.

Envista Stock Down 0.9 %

Shares of NYSE:NVST opened at $19.89 on Monday. Envista Holdings Co. has a 12 month low of $15.15 and a 12 month high of $25.64. The firm has a market cap of $3.42 billion, a P/E ratio of -2.56, a P/E/G ratio of 2.86 and a beta of 1.31. The company has a quick ratio of 1.77, a current ratio of 2.08 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $19.98 and its two-hundred day moving average price is $18.37.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. During the same quarter last year, the business posted $0.43 earnings per share. Envista’s revenue for the quarter was down 4.8% compared to the same quarter last year. As a group, research analysts forecast that Envista Holdings Co. will post 0.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on NVST shares. Mizuho initiated coverage on shares of Envista in a research report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target for the company. Evercore ISI increased their target price on Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research note on Thursday, October 31st. Robert W. Baird increased their price objective on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Finally, Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and lifted their price objective for the company from $16.00 to $23.00 in a report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.65.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.